Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. has launched a clinical study titled ‘EPIC-Peds’ to evaluate the safety, pharmacokinetics, and efficacy of the antiviral drugs nirmatrelvir and ritonavir in pediatric patients with COVID-19 who are not hospitalized but are at risk of severe disease. This study is significant as it aims to provide a treatment option for children under 18 years, potentially reducing the risk of severe COVID-19 outcomes in this vulnerable group.
The intervention involves administering nirmatrelvir and ritonavir, known for their antiviral properties, to patients in various age cohorts. The treatment is given orally, either as tablets or powder, twice daily for five days.
The study follows an interventional, open-label, single-arm design, meaning all participants receive the same treatment without a placebo group. The primary goal is to assess treatment efficacy and safety.
Key dates for the study include its start on February 25, 2022, with the latest update submitted on July 16, 2025. These dates are crucial for tracking the study’s progress and anticipated completion.
This study update could positively impact Pfizer’s stock performance by demonstrating the company’s commitment to addressing COVID-19 in pediatric populations. It may also influence investor sentiment favorably, especially if the study results are promising. Competitors in the pharmaceutical industry may closely watch these developments as they could reshape treatment protocols for children with COVID-19.
The study is currently ongoing, with further details available on the ClinicalTrials portal.